切换至 "中华医学电子期刊资源库"

中华普通外科学文献(电子版) ›› 2017, Vol. 11 ›› Issue (06) : 394 -398. doi: 10.3877/cma.j.issn.1674-0793.2017.06.008

所属专题: 文献

论著

术前短程辅助化疗对结直肠癌患者抑癌基因CDX2和生长抑制因子4表达的影响
孙健1, 顾晓华1, 侯卓2, 周晓俊3,()   
  1. 1. 226500 南通,江苏省如皋博爱医院普外科
    2. 226500 南通,江苏省如皋博爱医院放射介入科
    3. 215006 苏州大学附属第一医院胃肠外科
  • 收稿日期:2017-07-28 出版日期:2017-12-01
  • 通信作者: 周晓俊

Effect of preoperative short-term adjuvant chemotherapy on the expression of CDX2 and growth inhibitory factor 4 in colorectal cancer patients

Jian Sun1, Xiaohua Gu1, Zhuo Hou2, Xiaojun Zhou3,()   

  1. 1. Department of General Surgery, Rugao Boai Hospital, Nantong 226500, China
    2. Department of Radiology Interventional, Rugao Boai Hospital, Nantong 226500, China
    3. Department of Gastrointestinal Surgery, the First Hospital Affiliated of Suzhou University, Suzhou 215006, China
  • Received:2017-07-28 Published:2017-12-01
  • Corresponding author: Xiaojun Zhou
  • About author:
    Corresponding author: Zhou Xiaojun, Email:
引用本文:

孙健, 顾晓华, 侯卓, 周晓俊. 术前短程辅助化疗对结直肠癌患者抑癌基因CDX2和生长抑制因子4表达的影响[J/OL]. 中华普通外科学文献(电子版), 2017, 11(06): 394-398.

Jian Sun, Xiaohua Gu, Zhuo Hou, Xiaojun Zhou. Effect of preoperative short-term adjuvant chemotherapy on the expression of CDX2 and growth inhibitory factor 4 in colorectal cancer patients[J/OL]. Chinese Archives of General Surgery(Electronic Edition), 2017, 11(06): 394-398.

目的

探讨术前短程辅助化疗联合根治性手术治疗结直肠癌的临床疗效,评估术前短程化疗对结直肠癌患者组织CDX2和生长抑制因子4(ING4)表达的影响。

方法

回顾性分析2013年1月至2016年12月如皋博爱医院收治的112例结直肠癌患者资料,其中32例患者直接接受根治性手术切除病灶(对照组),80例在根治性手术前接受短程辅助化疗(研究组),采用免疫组织化学方法对两组活检组织中的CDX2和ING4表达进行定量分析,评估围手术期患者患者恢复情况,术后患者肛门排气时间、下床活动时间、住院时间、并发症发生情况,随访并应用Kaplan-Meier生存曲线进行单因素生存分析。

结果

(1)对照组和研究组患者的基本病理资料差异无统计学意义,具有可比性。(2) 2组治疗前CDX2和ING4的评分和阳性率均差异无统计学意义。化疗后研究组病灶样本中CDX2和ING4的免疫组化评分分别为8.33±1.86和8.86±2.31,阳性率分别为83.75%和72.50%,均显著高于对照组的5.86±2.41、6.83±1.57、59.38%、53.13%和化疗前水平的6.55±2.09、6.95±2.13、59.38%、57.50%。(3)与对照组相比,研究组患者的下床活动时间更早(P=0.033),但肛门排气时间和住院时长差异无统计学意义(P=0.235、0.332)。(4)随访39个月时,研究组死亡率显著低于对照组(6.25% vs 15.63%,P<0.05)。

结论

术前短程辅助化疗能显著提高结直肠癌患者肿瘤CDX2和ING4蛋白表达,对局部病灶有一定抑制作用,改善患者预后。

Objective

To evaluate the clinical efficacy of preoperative short-term adjuvant chemotherapy combined with radical surgery for colorectal cancer (CRC) patients, and the effect on the expression of tissue CDX2 and growth inhibitory factor 4 (ING4).

Methods

From January 2013 to December 2016, the data of one hundred and twelve patients with CRC in Rugao Boai Hospital were analyzed retrospectively. Thirty-two patients underwent radical resection (control group), 80 patients received short range adjuvant chemotherapy before radical surgery (test group). The biopsies expressions of CDX2 and ING4 in two groups were analyzed by immunohistochemistry. The recovery during perioperative period, anal exhaust time, ambulation time, hospitalization time and complications of the patients were analyzed. The follow-up data were collected for univariate survival analysis by Kaplan-Meier survival curves.

Results

(1) The basic pathological data of the patients between the two groups were not statistically significant. (2) The scoring and positive rates of CDX2 and ING4 were comparable between the two groups without significant difference. The post-operative histochemical scoring of CDX2 and ING4 of the test group were 8.33±1.86 and 8.86±2.31 (positive rate: 83.75% and 72.50%, respectively), significantly higher than the control group (5.86±2.41 and 6.83±1.57, positive rate: 59.38% and 53.13%) and pre-operative level (6.55±2.09 and 6.95±2.13, positive rate: 59.38% and 57.50%). (3) Compared with the control group, the ambulation time of the test group was earlier (P=0.033), while no statistically significant difference was detected for anal exhaust time (P=0.235) and hospitalization time (P=0.332). (4) The mortality rate of the test group during the 39-month follow-up was significantly lower than the control group (6.25% vs 15.63%, P<0.05).

Conclusion

Preoperative short-term adjuvant chemotherapy can significantly improve the expression of CDX2 and ING4 protein in colorectal cancer patients, and improve the prognosis by providing certain inhibitory effect on the lesion.

表1 112例结直肠癌患者的基本资料比较
表2 2组结直肠癌患者术前及化疗前后癌组织中CDX2和ING4的蛋白表达
表3 2组结直肠癌患者围手术期恢复情况
表4 2组结直肠癌患者住院期间并发症发生情况(例)
图1 2组大肠癌患者的生存曲线
[1]
姚宏伟,姚响芸,孙涛, 等. 腹腔镜结直肠癌根治性切除联合同期腹腔镜或开腹肝大部切除术治疗同时性结直肠癌肝转移的疗效分析[J]. 中华消化外科杂志, 2016, 15(2):128-134.
[2]
于广计,刘松,王庆东. 射频消融联合小剂量卡培他滨化疗治疗老年大肠癌术后肝转移的临床疗效分析[J/CD]. 中华普通外科学文献(电子版), 2016, 10(4):251-255.
[3]
梁寒,郝希山. 直肠癌的辅助性放化疗[J]. 中国肿瘤临床, 2003, 30(2):148-152.
[4]
Dalerba P, Sahoo D, Paik S, et al. CDX2 as a prognostic biomarker in stageⅡ and stageⅢ colon cancer[J]. N Engl J Med, 2016, 374(3):211-222.
[5]
Nanding A, Tang L, Cai L, et al. Low ING4 protein expression detected by paraffin-section immunohistochemistry is associated with poor prognosis in untreated patients with gastrointestinal stromal tumors[J]. Gastric Cancer, 2014, 17(1):87-96.
[6]
Reggiani Bonetti L, Lionti S, Vitarelli E, et al. Prognostic significance of CDX2 immunoexpression in poorly differentiated clusters of colorectal carcinoma[J]. Virchows Arch, 2017.[Epub ahead of print]
[7]
韦皓棠,陈利生,董保国, 等. CDX2及CK20在结直肠癌中的表达及其临床意义[J]. 结直肠肛门外科, 2015, 21(1):28-31.
[8]
张新星,于瑞莲,代小松, 等. MCM7和CDX2蛋白在Ⅱ期结直肠癌组织中的表达及意义[J]. 世界华人消化杂志, 2015, 23(3):495-501.
[9]
Qu H, Yin H, Yan S, et al. Inhibitor of growth 4 suppresses colorectal cancer growth and invasion by inducing G1 arrest, inhibiting tumor a/ngiogenesis and reversing epithelial-mesenchymal transition[J]. Oncol Rep, 2016, 35(5):2927-2935.
[10]
刘俊远,黄桂林,张玉婷. 生长抑制因子4和人表皮生长因子受体2在结直肠癌中的表达及其与预后的关系[J]. 中国全科医学, 2014, 17(29):3469-3472.
[11]
刘俊远,黄桂林,李志刚, 等. ING4和CDX2在结直肠癌中的表达及其与预后的关系[J]. 天津医药, 2014, 42(2):131-134.
[12]
沈依. 奥沙利铂联合五氟尿嘧啶术前短程冲击化疗对大肠癌组织survivin基因表达的影响[D]. 苏州:苏州大学, 2014.
[13]
董帅军,韩保卫,王战会, 等. 结直肠癌切除术后开始辅助化疗延迟的独立影响因素分析[J]. 中华实验外科杂志, 2015, 32(6):1421-1423.
[14]
韩加刚,李志霞,安大立, 等. 术前区域动脉灌注化疗对大肠癌患者血清血管内皮生长因子和内皮抑素的影响[J]. 中华普通外科杂志, 2006, 21(2):135-137.
[15]
丁小兵,李玉梅,邹叶青. 新辅助化疗、术中动脉灌注化疗对结直肠癌患者VEGF的影响[J]. 实用癌症杂志, 2016, 31(10):1678-1680.
[16]
Markovina S, Youssef F, Roy A, et al. Improved metastasis- and disease-free survival with preoperative sequential short-course radiation therapy and FOLFOX chemotherapy for rectal cancer compared with neoadjuvant Long-Course Chemoradiotherapy: Results of a Matched Pair Analysis[J]. Int J Radiat Oncol Biol Phys, 2017, 99(2):417-426.
[1] 罗青杉, 梅海涛, 郝家领, 蔡锦锋, 周润楷, 温玉刚. 连接蛋白43通过调控细胞周期抑制结直肠癌的增殖机制研究[J/OL]. 中华普通外科学文献(电子版), 2024, 18(05): 344-349.
[2] 罗文斌, 韩玮. 胰腺癌患者首次化疗后中重度骨髓抑制的相关危险因素分析及预测模型构建[J/OL]. 中华普通外科学文献(电子版), 2024, 18(05): 357-362.
[3] 徐逸男. 不同术式治疗梗阻性左半结直肠癌的疗效观察[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 72-75.
[4] 韩加刚, 王振军. 梗阻性左半结肠癌的治疗策略[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 450-458.
[5] 梁轩豪, 李小荣, 李亮, 林昌伟. 肠梗阻支架置入术联合新辅助化疗治疗结直肠癌急性肠梗阻的疗效及其预后的Meta 分析[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 472-482.
[6] 严虹霞, 王晓娟, 张毅勋. 2 型糖尿病对结直肠癌患者肿瘤标记物、临床病理及预后的影响[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 483-487.
[7] 赵磊, 刘文志, 林峰, 于剑, 孙铭骏, 崔佑刚, 张旭, 衣宇鹏, 于宝胜, 冯宁. 深部热疗在改善结直肠癌术后辅助化疗副反应及生活质量中的作用研究[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 488-493.
[8] 黄海洋, 邝永龙, 陈嘉胜. 基层医院结直肠肿瘤经自然腔道取标本手术30 例分析[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 510-518.
[9] 任佳琪, 刁德昌, 何自衍, 张雪阳, 唐新, 李文娟, 李洪明, 卢新泉, 易小江. 网膜融合线导向的脾曲游离技术在左半结肠癌根治术中的应用[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(05): 362-367.
[10] 张迪, 王春霞, 张学东, 李发馨, 庞淅文, 陈一锋, 张维胜, 王涛. 梗阻性左半结直肠癌自膨式金属支架置入后行腹腔镜手术与开腹手术的短期临床疗效比较[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(05): 375-380.
[11] 张蔚林, 王哲学, 白峻阁, 黄忠诚, 肖志刚. 利用TCGA数据库构建基于miRNA的结直肠癌列线图预后模型[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(05): 381-388.
[12] 张伟伟, 陈启, 翁和语, 黄亮. 随机森林模型预测T1 期结直肠癌淋巴结转移的初步研究[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(05): 389-393.
[13] 季鹏程, 鄂一民, 陆晨, 喻春钊. 循环外泌体相关生物标志物在结直肠癌诊断中的研究进展[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(04): 265-273.
[14] 李佳莹, 王旭丹, 梁雪, 张雷, 李佳英. 1990~2021年中国结直肠癌死亡趋势分析[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(04): 274-279.
[15] 戈伟, 陈刚. 纳米炭导航行淋巴示踪在结直肠癌TNM分期中淋巴分期价值的临床研究[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(04): 288-293.
阅读次数
全文


摘要